Controlled Clinical Trial of Antilymphocyte Globulin in Patients With Renal Allografts From Cadaver Donors

Sheil, A. G. R.; Kelly, Graham; Storey, B. G.; May, James R.; Kalowski, Steven; Mears, D. C.; Rogers, J. H.; Johnson, James R.; Charlesworth, J. A.; Stewart, John H.

doi:10.1016/s0140-6736(71)92206-9

Cited by 58 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In acute rejection intravenous bolus methylprednisolone 500-1000 mg was given daily for one to three days, and the dose of oral prednisone was then gradually tapered to the prerejection dose. As part of a clinical trial antilymphocyte globulin was used in alternate patients from September 1968, and it was used in all patients from 1972.11 12 From 1967 to 1969 blood transfusions were used liberally in our dialysis protocols, but after 1969 they were withheld before transplantation unless strong clinical indications existed. A deliberate pretransplant blood transfusion programme was not started until September 1980.…”

Section: Methodsmentioning

confidence: 99%

Long-term survival after cadaveric renal transplantation.

Savdie¹,

Mahony²,

Caterson³

et al. 1982

BMJ

View full text Add to dashboard Cite

In a series of 404 consecutive first cadaver kidney transplants performed since 1967 the actuarial five-and 10-year survival of patients were 61% and 47% respectively and of grafts 46% and 36%. In more than four-fifths of the patients surviving these intervals the original cadaveric grafts were functioning at these times, and most of the remainder were sustained by subsequent grafts. Although graft survival has remained static since 1967, patient survival improved. Results for 43 consecutive second cadaver transplants were similar after five years to those of first grafts.These results promote the acceptability of cadaveric transplantation as a long-term treatment for chronic renal failure.

show abstract

Section: Methodsmentioning

confidence: 99%

Long-term survival after cadaveric renal transplantation.

Savdie¹,

Mahony²,

Caterson³

et al. 1982

BMJ

View full text Add to dashboard Cite

show abstract

“…No influence on patient survival was observed (57, 103,104). Prospective studies will, however, have to decide about the real value of A L G treatment in allotransplantation.…”

Section: A L G and Patient And Graft Survivalmentioning

confidence: 99%

Analysis of 330 Necro-Kidney-Allografts (Part 2 of 2)

1979

Eur Surg Res

View full text Add to dashboard Cite

“…Antilymphocyte globulin has been used very widely with variaible effect. In a controlled clinical trial Sheil et al 4 showed that a course of antilymphocyte globulin lasting a few weeks can improve overall graft survival by about 10-15%. Patients receiving antilymphocyte globulin are, however, very prone to develop fungal infections, and deaths from this cause have tended to cancel out the benefits from controlling rejection.56…”

Section: For Debatementioning

confidence: 99%

Death after kidney transplantation.

Salaman¹

1974

BMJ

View full text Add to dashboard Cite

Controlled Clinical Trial of Antilymphocyte Globulin in Patients With Renal Allografts From Cadaver Donors

Cited by 58 publications

References 8 publications

Long-term survival after cadaveric renal transplantation.

Long-term survival after cadaveric renal transplantation.

Analysis of 330 Necro-Kidney-Allografts (Part 2 of 2)

Death after kidney transplantation.

Contact Info

Product

Resources

About